EUVIMEDEUVIMED entdecken
Crossref

Corneal Targeted Mucoadhesive Emulsion for Prolonged Delivery of Voriconazole: Formulation Evaluation and Pharmacokinetic Assessment

Amol Chhatrapati Bisen iD, Saurabh Srivastava, Sachin Nashik Sanap iD, Anjali Mishra, Arpon Biswas iD, Sristi Agrawal iD, Rabi Sankar Bhatta iD

Biopharmaceutics & Drug Disposition · 11.04.2026

DOI: 10.1002/bdd.70028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 11.04.2026. Verfasst von Amol Chhatrapati Bisen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Voriconazole, a broad‐spectrum triazole antifungal, is widely prescribed for fungal keratitis (FK) caused by Candida , Aspergillus , and Fusarium species. Conventional ophthalmic solutions are limited by rapid clearance and low bioavailability. This study describes the development of a voriconazole‐loaded ophthalmic emulsion to improve ocular residence and drug disposition. Emulsions were prepared with soybean oil and Tween 80 via high‐shear homogenization, with batch VE‐3 exhibiting favorable properties, including nanosized globules (95.8 ± 50.2 nm, PDI 0.197), pH 6.94 ± 0.14, high drug content (104.55% ± 7.9%), and physicochemical stability. DSC confirmed the absence of drug–excipient interactions, whereas osmolality (280 ± 4 mOsm/L) and conductance (77.59 ± 1.7 S/m) demonstrated ocular compatibility. To enhance mucoadhesion and prolong corneal residence, chitosan was incorporated into VE‐3, yielding CS‐VE‐3. In vitro release studies showed 81% drug release from VE‐3 versus 65% from CS‐VE‐3, with the latter following Higuchi kinetics, consistent with sustained release. Ex vivo transcorneal studies revealed comparable permeation for VE‐3 (43.2% ± 1.14%) and CS‐VE‐3 (47% ± 1.22%), but distinct drug retention profiles (11.41% ± 0.73% vs. 5.09% ± 0.30%). In vivo pharmacokinetic assessment demonstrated C max values of 9.66 ± 3.49 μg/mL (marketed), 10.47 ± 6.43 μg/mL (VE‐3), and a four‐folds higher 41.67 ± 28.48 μg/mL for CS‐VE‐3, indicating prolonged corneal contact with chitosan incorporation. Ocular irritation studies confirmed safety and tolerability. The optimized mucoadhesive emulsion offers a promising strategy for sustained ocular delivery of voriconazole, potentially improving therapeutic outcomes in FK management.

Schlagwörter

Stichwörter der Autor:innen

emulsionfungal keratitisprecorneal residencesustained releasetopicular administrationvoriconazole

Autor:innen und Institutionen

  • Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.
  • Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
  • ICMR-National Institute for Pre-Clinical Research (NIPCR), Hyderabad, Telangana, India.

ORCID-Profile: Amol Chhatrapati Bisen, Sachin Nashik Sanap, Arpon Biswas, Sristi Agrawal, Rabi Sankar Bhatta

Zitieren

APA

Bisen, A. C., Srivastava, S., Sanap, S. N., Mishra, A., Biswas, A., Agrawal, S., & Bhatta, R. S. (2026). Corneal Targeted Mucoadhesive Emulsion for Prolonged Delivery of Voriconazole: Formulation Evaluation and Pharmacokinetic Assessment. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.70028

Vancouver

Bisen AC, Srivastava S, Sanap SN, Mishra A, Biswas A, Agrawal S, et al. Corneal Targeted Mucoadhesive Emulsion for Prolonged Delivery of Voriconazole: Formulation Evaluation and Pharmacokinetic Assessment. Biopharmaceutics & Drug Disposition. 2026. doi:10.1002/bdd.70028

BibTeX
@article{Bisen2026,
  author = {Bisen, Amol Chhatrapati and Srivastava, Saurabh and Sanap, Sachin Nashik and Mishra, Anjali and Biswas, Arpon and Agrawal, Sristi and Bhatta, Rabi Sankar},
  title = {Corneal Targeted Mucoadhesive Emulsion for Prolonged Delivery of Voriconazole: Formulation Evaluation and Pharmacokinetic Assessment},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2026},
  doi = {10.1002/bdd.70028}
}
Kostenlos starten →